Abstract: Seventy years ago it was discovered that glutamate is abundant in the brain and that it plays a central role in brain metabolism. However, it took the scientific community a long time to realize that glutamate also acts as a neurotransmitter. Glutamate is an amino acid and brain tissue contains as much as 5 -15 mM glutamate per kg depending on the region, which is more than of any other amino acid. The main motivation for the ongoing research on glutamate is due to the role of glutamate in the signal transduction in the nervous systems of apparently all complex living organisms, including man. Glutamate is considered to be the major mediator of excitatory signals in the mammalian central nervous system and is involved in most aspects of normal brain function including cognition, memory and learning. In this review, the basic biology of the excitatory amino acids glutamate, glutamate receptors, GABA, and glycine will first be explored. In the second part of this review, the known pathophysiology and pathology will be described. (J Toxicol Pathol 2008; 21: 25-51) 
Introduction and Overview
In the first decades of the 20th century, research into the chemical mediation of the "autonomous" (autonomic) nervous system (ANS) was an area that received much research activity. In England, William Maddock Bayliss, Ernest Henry Starling, Henry Dale and T.R. Elliot were investigating the actions and properties of this system following the recent identification of acetylcholine and adrenaline. In Vienna, Austria, Otto Loewi provided the first reliable evidence for the existence of chemical transmission by acetylcholine in 1921, then other chemical mediators b e t w e e n 1 9 2 9 a n d 1 9 3 6 
. L o e w i d o u b t e d t h a t neurotransmitters operated in the voluntary nervous system, b u t t h e d i s c o v e r y t h a t a c e t y l c h o l i n e i s a l s o a
neurotransmitter in the neuromotor synapse, and that preganglionic synapses in the ANS are all cholinergic, in contrast with the postganglionic cholinergic or adrenergic receptors, proved him incorrect. Later it was found that the transmitter acting in adrenergic synapses was not adrenalin (epinephrine) but noradrenalin (norepinephrine) 1 . We now recognize three major categories of substances that act as neurotransmitters. These are amino acids (primarily glutamic acid, γ-amino butyric acid, aspartic acid and glycine), peptides (vasopressin, somatostatin, neurotensin, etc.), and monoamines (norepinephrine, dopamine and serotonin) plus acetylcholine.
Glutamatergic synaptic transmission in the mammalian central nervous system (CNS) was slowly established over a period of some 20 years, dating from the 1950s [2] [3] [4] . Realization that glutamate and similar excitatory amino acids (EAAs), such as domoic acid, mediated their excitatory actions via multiple receptors preceded establishment of these receptors as synaptic transmitter receptors 5 . EAA receptors were initially classified as N-methyl-D-aspartate (NMDA) and non-NMDA receptors.
Non-NMDA glutamate receptors were subdivided into α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (also known as AMPA receptor, AMPAR, or quisqualate receptor) and kainate (Ka) receptors following experiments with agonists that appeared to activate these receptors preferentially. In addition, their sensitivity to a range of differentially acting antagonists was understood during the 1970s. NMDA receptors were definitively shown to be synaptic receptors on spinal neurons by the sensitivity of certain excitatory pathways in the spinal cord to a range of specific NMDA receptor antagonists. However, specific NMDA receptor antagonists appeared to be less effective at synapses in higher centers. In contrast, antagonists that also blocked non-NMDA as well as NMDA receptors were almost universally effective at blocking synaptic excitation within the brain and spinal cord, establishing both the existence and ubiquity of non-NMDA synaptic receptor systems throughout the CNS 6 .
In the early 1980s, NMDA receptors were shown to be involved in several central synaptic pathways, acting in concert with non-NMDA receptors under conditions where a protracted excitatory postsynaptic potential was seen in response to intense stimulation of presynaptic fibers. Such activation of NMDA receptors together with non-NMDA receptors led to the phenomenon of long-term potentiation (LTP) 7 . LTP is associated with lasting changes in synaptic efficacy (synaptic plasticity) and has been considered to be an important process in memory 8 and learning 9 . During the same period, it was shown that certain glutamate receptors (GluRs) in the brain mediated biochemical changes that were not susceptible to NMDA or non-NMDA receptor antagonists. This dichotomy was resolved in the early 1990s using molecular biology, which identified two families of glutamate binding receptor proteins: ionotropic (iGluR) and metabotropic (mGluR) glutamate receptors 10 . Development of antagonists binding to specific protein subunits is currently enabling precise identification of discrete iGluR or mGluR subtypes 11 that participate in a range of central synaptic processes, including synaptic plasticity [12] [13] [14] .
It is the purpose of this review to summarize the biological activities of the glutamate system (Part I) and to relate changes in these receptors to normal physiology and disease entities (Part II). Efforts have been made to address the toxicologic pathology of these receptors wherever possible; however, although the literature has a number of e x a m p l e s o f r e c e p t o r v i s u a l i z a t i o n b y immunohistochemistry, the role of these receptors in abnormal morphology is still under intense investigation.
The Glutamate System
A number of authors have discussed the importance of the glutamate system, e.g., [15] [16] [17] [18] , and its regulation 19, 20 . The following discussion not only addresses, glutamate, GABA, and glycine but also details how excitatory amino acids may interact with the glutamate system.
Excitatory amino acids (EAAs)
Glutamate (Glu) and aspartate (Asp) are amino acids (AAs) that act as major excitatory neurotransmitters in the mammalian central nervous system [21] [22] [23] [24] [25] by stimulating or exciting postsynaptic neurons. Although these AAs are primarily involved in intermediary metabolism and other non-neuronal functions, their most important role is as neurotransmitters. It is estimated Glu mediates nearly 50% of all the synaptic transmissions in the CNS and its involvement is implicated in nearly all aspects of normal brain function including learning, memory, movement, cognition and development 21, [26] [27] [28] [29] [30] [31] [32] [33] [34] . These EAAs and their various analogues can be neurotoxic, particularly when they excessively stimulate the same excitatory receptors, which is a phenomenon known as excitotoxicity 21, 22, 24, 25, 35, 36 . At elevated concentrations, Glu acts as a neurotoxin capable of inducing severe neuronal damage and necrosis by causing over excitation of neurons [37] [38] [39] [40] [41] . Previously it was thought that hypoxia played a part in the neurotoxicity of Glu, particularly in the white matter; however, it has now been shown that hypoxic injury and GluRs over stimulation are independent of one another 42 . EAAs access the brain tissue of the circumventricular organs located outside the blood brain barrier (BBB) [43] [44] [45] . Despite the BBB protective mechanisms, the local or circulating concentrations of these excitatory compounds may be great enough to induce damage leading to neurotoxic exposure levels. The toxicity of each EAA compound varies according to the potency, the chemical availability, the rate of absorption, the affinity to specific receptors and the particular anatomical target site [46] [47] [48] . In addition, the susceptibility, genetic predisposition and health status of the individual are also important factors.
Excitotoxicity
The neurotoxic effects of the EAAs are dependent on the species, developmental stage of the animal, type of agonist, duration of exposure to the agonist and the cellular expression of the GluR subtypes. Regardless, neurons under various conditions can become so over stimulated by Glu that it actually kills them through receptor-mediated depolarization and calcium (Ca ++ ) influx 49, 50 . There are five main factors necessary for the transition of Glu and Asp from neurotransmitters to excitotoxins. These include inadequate neuronal ATP levels, inadequate neuronal levels of magnesium (Mg ++ ); high concentrations of inflammatory prostaglandins; excessive free radical formation 51, 52 , and inadequate removal of synaptic Glu 53, 54 . An array of GluRs is known to be present on pre-and post-synaptic membranes that are used to transduce integrated signals using an increased ion flux and second messenger pathways 21, 24, 25, 33, 34, [55] [56] [57] . It is the excessive activation of these receptors that leads to neurotoxicity, often referred to as "excitotoxicity" 58 . In addition, it has been postulated that excitotoxicity is involved in the pathogenesis of many types of acute and chronic insults to the CNS 59 and peripheral tissues 60, 61 . The AAs, Glu and Asp, including structurally similar compounds, can be dietary excitotoxins 62 . Domoic acid (DA) is one of the most potent neurotoxins in seafood that can enter our food supply 63 . Contamination of mussels by the sea diatoms producing DA was found to be the reason for the outbreak of the lethal shellfish poisoning that occurred in Canada in 1987 [65] [66] [67] . The clinical manifestations of DA intoxication are related to its effect in the brain including severe seizures [63] [64] [65] [66] [67] [68] [69] [70] [71] and survivors of severe cases suffered permanent loss of short-term memory, a phenomenon that lead to the term amnesic shellfish poisoning 66 . However, the other clinical symptoms such as gastrointestinal disturbances, cardiovascular collapse and cardiac arrhythmia 43, 63, 70, 72 have also been noted, and could be related to the DA poisoning 60 . Recently, DA poisoning in California Sea Lions has been reported 73 .
Disturbance of Glu homeostasis probably plays a pivotal role in the execution of pathological changes in many disease states involving the tissues listed above. There may be a number of factors that trigger the neurotoxic potential of endogenous Glu including increase in Glu release, malfunctioning of neuronal and glial uptake, energy deficits, neuronal depolarization, changes in GluR properties or expression patterns, free radical formation and others 49, 50, [74] [75] [76] [77] . Excitotoxicity has also been suggested as a central mechanism in fluoride neurotoxicity 78, 79 . Such excitotoxic effects can be pronounced during acute events such as ischemic stroke and trauma, or milder but prolonged in chronic neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis 76, [80] [81] [82] . As will be discussed in the second article of this series, glutamatergic dysfunction is also involved in the symptomatology of disorders such schizophrenia, anxiety, and depression 50, 74 . In addition, glutamatergic dysfunction has been regarded as part of the development of disorders associated with longterm plastic changes in the CNS such as chronic pain, drug tolerance, dependence, addiction, partial complex seizures and tardive dyskinesia 50, 74, 83, 84 . It has been suggested that monosodium glutamate (MSG) is toxic and can exert its toxicity via similar mechanisms to L-glutamate (L-Glu). Administration of MSG during the neonatal period produces marked cognitive effects due to the loss of synaptic plasticity in rodents 85 ; however, the effect of MSG on long-term brain function in humans has been questioned 86 . The route of administration can explain the differences in these findings, where human exposure is much lower occurring via the oral route.
Glutamate, gamma aminobutyric acid, and glycine
Historically, AAs (including Glu and Asp) were studied in the context of their importance in protein synthesis, but in the 1950s the focus of research shifted as AAs became recognized as putative neurotransmitters. For compounds to be classified as neurotransmitters they show several characteristics in common 87, 88 . These characteristics are: the neurotransmitter is synthesized, stored, and released from the presynaptic terminal; specific neurotransmitter receptors are localized on the postsynaptic cells; and there exists a mechanism to stop neurotransmitter release and clear molecules from the cleft. Glu was found to fulfill the r e q u i r e m e n t s a b o v e a n d t h u s w a s n a m e d a neurotransmitter 89 . Although many AAs play a role in neurotransmission, Glu, glycine (Gly), and γ-aminobutyric acid (GABA) are a m o ng t he m or e c o mm o n a n d b e t te r-u nd e r s t oo d neurotransmitters 7 4 , 9 0 , 9 1 . They are all metabolic intermediates and neurotransmitters, where Glu is the major excitatory neurotransmitter, and Gly and GABA are the major inhibitory neurotransmitters, in the CNS 92 . Glu, which is synthesized, stored, and released from the presynaptic terminal, has specific neurotransmitter receptors localized on the postsynaptic cells, and is eliminated from the synaptic cleft by specific transporters: it is a neurotransmitter.
L-Glu acts through both ligand-gated ion channels at ionotropic receptors (iGluR) and at G-protein coupled metabotropic receptors (mGluR). As will be discussed in more detail later, activation of these receptors is responsible for basal excitatory synaptic transmission and many forms of synaptic plasticity such as long-term potentiation (LTP) and long-term depression (LTD), which are thought to underlie learning and memory 91 .
1) Glutamate
Glu has a number of functions that are listed in Table 1 . a) Glutamate synthesis Glu is enzymatically created from α-ketoglutarate via GABA transaminase as is shown in Fig. 2 93 . N-Acetyl-aspartyl-glutamate (NAAG) is abundant in the mammalian CNS, which has led to the hypothesis that this dipeptide is the storage form of Glu. The membrane bound metallopeptidase NAALADase (N-acetyl-a-linkedacidic dipeptidase, or glutamate carboxypeptidase II, E.C. 3.4.17.21 ) is co-localized with NAAG in the CNS and converts NAAG to N-Acetyl-aspartate (NAA) and Glu 94 . It seems likely that NAAG is also a weak partial agonist at Nmethyl-D-aspartic acid (NMDA) 95 . This effect is seen at concentrations beyond therapeutically relevant levels. Inhibition of NAALADase could be useful in numerous CNS disorders associated with disturbances in glutamatergic transmission by decreasing the concentration of Glu and increasing the concentration of NAAG 96 . b) Glutamate uptake Brain tissue has a remarkable ability to accumulate Glu, an ability resulting from glutamate transporter proteins (GluTP) present in the plasma membranes of both glial cells and neurons 97 . Glu and its structural analogues may enter the food supply during preparation or processing as contaminants or additives in its free form or bound to peptides and proteins [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [98] [99] [100] [101] . These analogues include monosodium glutamate (MSG), L-aspartate, L-cysteine, related sulfur AAs, B-N -oxalyamino-L-alanine (BOAA or ODAP), B-N-methyl-amino-L-alanine (BMAA) and the seafood toxin domoic acid (DA) 21, 63, 64, [99] [100] [101] [102] [103] [104] . From Glu labeling studies, the average concentration of Glu in ganglion cells is five mM 105 . Physiological studies using isolated cells indicate that only µM levels of Glu are required to activate GluR [106] [107] [108] . Thus, the amount of Glu released into the synaptic cleft is several orders of magnitude higher than the concentration required for activating most postsynaptic receptors. c) Glutamate metabolism Two key goals of brain AA handling are to maintain a very low intrasynaptic concentration of glutamic acid and also to provide the system with precursors from which to synthesize Glu. The intrasynaptic Glu level must be kept low to maximize the signal-to-noise ratio upon the release of Glu from nerve terminals, and to minimize the risk of excitotoxicity consequent to excessive glutamatergic stimulation of susceptible neurons. Additionally, the brain must also provide neurons with a constant supply of Glu, which both neurons and glia robustly oxidize. Astrocytes, which are in close approximation to brain capillaries, probably are the initial site of metabolism of Glu. Astrocytes release the cognate ketoacid [α-ketoisocaproate (KIC)] to neurons, which have a cytosolic branched-chain aminotransferase that reaminates the KIC to leucine, in the process consuming Glu and providing a mechanism for the buffering of Glu if concentrations become excessive 109 . The liver is the major site of gluconeogenesis, the major organ of AA catabolism and the only organ with a complete urea cycle 110 . It has been suggested that these AAs are oxidized in the liver; however, total oxidation cannot occur within the confines of hepatic oxygen uptake and ATP homeostasis. Rather, most AAs are oxidized only partially in the liver, with the bulk of their carbon skeleton being converted to glucose. The nitrogen is converted to urea and, to a lesser extent, to glutamine. The integration of the urea cycle with gluconeogenesis ensures that the bulk of the reducing power (NADH) required in the cytosol for gluconeogenesis can be provided by ancillary reactions of the urea cycle 111 . Glu is at the center of these metabolic events. It is central because of the well-described transdeamination system involving aminotransferases and Glu dehydrogenase, where Glu plays a key catalytic role in the removal of α-amino nitrogen from AAs. In addition, the "glutamate family" of AAs (arginine, ornithine, proline, histidine and glutamine) requires the conversion of these AAs to Glu for their metabolic disposal. Finally, Glu serves as substrate for the synthesis of N-acetylglutamate, an essential allosteric activator of carbamyl phosphate synthetase I, a key regulatory enzyme in the urea cycle 112 .
d) Glutamate clearance
It has been calculated that a 70-kg man has a daily Glu intake of approximately 28 g that is derived from the diet and from the breakdown of gut proteins. The daily Glu turnover in the body is about 48 g. Glu is eliminated from the synaptic cleft by specific transporters. Despite this large turnover, the total pool of Glu in blood is quite small, approximately 20 mg, because of its rapid extraction from and utilization by various tissues, particularly muscle and liver 113, 114 . In the CNS, Glu clearance and, as a consequence, Glu concentration and diffusion in the extracellular space, is associated with the degree of astrocytic coverage of its neurons 115 . e) Glutamate transporters (GluTPs)
Brain tissue has a remarkable ability to accumulate Glu, an ability due to GluTPs present in the plasma membranes of both glial cells and neurons. GluTPs represent the only significant mechanism for removal of Glu from the extracellular fluid and are important for the long-term maintenance of low and non-toxic concentrations of Glu and appear to have more sophisticated functions in the modulation of neurotransmission 97 . They may modify the time course of synaptic events 116 , the extent and pattern of activation and desensitization of receptors outside the synaptic cleft and at neighboring synapses (intersynaptic cross talk).
The genes encoding GluTPs have been cloned both from rats and humans 117, 118 . The human transporters EAAT1 and EAAT2 (rat equivalents GLAST and GLT1) are found in astroglia and microglia widely distributed throughout the CNS. The highest concentration can be found in the cortex. Human EAAT3 (rat EAAC1) is thought to be restricted to neurons; however, it also has been found outside of the CNS. More restrictively, human EAAT4 is expressed only by cerebellar neurons. Further investigation into the neuronal vesicular Glu transporter uncovered VGLUT1, which is only expressed in glutamatergic neurons 119, 120 . GluTPs provide Glu for synthesis of GABA, glutathione and protein, which can be used structurally, or for energy production 97 . Glu uptake appears to be modulated molecularly on virtually all possible levels including DNA transcription, mRNA splicing and degradation, protein synthesis and targeting, actual AA transport activity and associated ion channel activities. A number of soluble compounds, including Glu, cytokines, and growth factors, influence the GluTP expression and activities 121 . GluTPs have been identified in a number of neural tissues where they assist in maintaining appropriate concentrations of Glu at its synaptic site. Many tissues demonstrate Glu, GluR and GluTPs, including but not limited to, CNS 122 , autonomic and sensory ganglia 123 , peripheral nerves-myelinated and unmyelinated 124, 125 , vagus and other cholinergic nerves 124 , tachykinin containing sensory nerves and vestibular tissues 1 , ileal longitudinal muscle [155] [156] [157] , h e pa to c yt e s 6 8 , 1 5 8 , k i d n e y , s p l e e n s , o v a r i e s 4 8 , 1 5 9 , lungs 60, 99, 145, 148, 154, [158] [159] [160] [161] [162] [163] [164] [165] , heart 60, 99, 145, 148, 154, [158] [159] [160] [161] [162] [163] [164] [165] , bone 159, 165 , bone marrow 159 , rat glaborous skin 166 , and keratinocytes 163 . In the CNS, high affinity GluTPs located on adjacent neurons and surrounding glial cells rapidly remove Glu from the synaptic cleft to prevent cell death [167] [168] [169] . Five GluTPs, EAAT-1 (or GLAST), EAAT-2 (or GLT-1), EAAT-3 (or EAAC-1), EAAT-4, and EAAT-5, have been cloned [169] [170] [171] [172] [173] [174] . GluTPs are pharmacologically distinct from both iGluRs and mGluRs and L-Glu, L-Asp, and D-Asp are s u b s t r a t e s f o r t h e t r a n s p o r t e r s 1 2 9 , 1 3 0 , 1 7 5 ; G l u R agonists 129, 130, 175, 176 and antagonists 130, 177 are not. Glu uptake can be blocked by the transporter blockers dihydrokainate (DHKA) and DL-threo-β-hydroxyaspartate (HA) 130, 177 . GluTPs incorporate Glu into cells along with the cotransport of three Na + ions 175, 178 and the antiport of one K + ion 178, 179 and either one OH-or one HCO 3 -ion 179 . The excess Na + ions generate a net positive inward current, which drives the transporter 175, 178 . In addition, a Glu-elicited c h l o r i d e c u r r e n t i s a l s o a s s o c i a t e d w i t h s o m e transporters 174, 179 .
GluTPs located in the plasma membrane of neuronal and glial cells are different from the GluTPs located on synaptic vesicles within presynaptic terminals. The transporters in the plasma membrane transport Glu in a Na + and voltage-dependent manner independent of Cl -168,175,178 . L-Glu, L-Asp, and D-Asp are substrates for these transporters 175 . In contrast, the vesicular transporter selectively concentrates Glu into synaptic vesicles in a Na + -independent, ATP-dependent manner [180] [181] [182] that requires Cl -181-185 . The pharmacology of GluR is similar to that described for GluTPs, as the Glu-elicited current is dependent upon external Na + , reduced by transporter blockers, and insensitive to Glu agonists and antagonists. However, altering internal Na + concentration does not change the reversal potential 183 or the amplitude 185, 186 of the Glu-elicited current, suggesting GluR is distinct from GluTPs.
2) Gamma-Aminobutyric Acid (GABA) I n 1 9 5 0 , γ -A m i n o b u t y r i c a c i d ( G A B A ) w a s independently identified in the vertebrate brain 187, 188 . These investigators also demonstrated the presence of glutamic acid decarboxylase (GAD) in mouse brain and showed that the active enzyme, capable of decarboxylating Glu to GABA, required pyridoxal 5-phosphate (PLP) as cofactor 189 . Early electrophysiological work carried out, primarily in crustaceans, firmly established GABA as an inhibitory neurotransmitter in invertebrates 190 . Although GABA was originally shown to be present in very high, up to millimolar, concentrations in the vertebrate CNS, it proved considerably more difficult to unequivocally establish its role as a neurotransmitter in the mammalian brain. However, by the early 1970s, GABA had been shown to satisfy all of the classical criteria of a neurotransmitter 191, 192 . The establishment of the role of GABA as a neurotransmitter was hampered by the widespread distribution of GABAergic neurons throughout the CNS, and the lack of suitable reagents to positively identify G A B A e r g i c n e u r o n s . T h e r o l e o f G A B A a s a neurotransmitter is that of inhibitory neurotransmission, although this property has been questioned recently 193 . Following the purification of GAD and the generation of GAD antisera, immunohistochemical studies revealed that many GABAergic neurons in the brain are interneurons and are therefore uniquely able to alter the excitability of local circuits within a given brain region 192 . From these and other studies it was confirmed that 30-40% of all CNS neurons utilize GABA as their primary neurotransmitter. a) GABA: Synthesis, uptake, and metabolism GABA is formed in vivo via a metabolic pathway called the "GABA shunt". The initial step in this pathway utilizes α-ketoglutarate formed from glucose metabolism via the Krebs cycle. α-Ketoglutarate is then transaminated by α-oxoglutarate transaminase (GABA-T) to form Glu, the im m e d i a t e p r e c u r s or of G AB A . F i na ll y , Gl u i s decarboxylated to form GABA by the GAD 189, 192 . GAD is expressed only in GABAergic neurons and in certain Like most neurotransmitters, GABA is stored in synaptic vesicles and is released in a Ca ++ -dependent manner upon depolarization of the presynaptic membrane. Following release into synaptic cleft, GABA's actions are terminated principally by reuptake into presynaptic terminals and surrounding glia. GABA is also metabolized by GABA-T to form succinic semialdehyde. This transamination regenerates Glu when it occurs in the presence of α-ketoglutarate. Next, succinic semialdehyde is oxidized by succinic semialdehyde dehydrogenase (SSADH) to succinic acid, which then reenters the Krebs cycle.
The reuptake of GABA occurs via highly specific transmembrane transporters, which have recently been shown to be members of a large family of Na + -dependent neurotransmitter transporters. GABA uptake is temperatureand ion-dependent and both Na + and Cl -ions are required for optimal uptake.
Affinity purification of the GABA transporter protein has recently led to its molecular cloning 194 . The principal neuronal GABA transporter is a 70-to 80-kDa glycoprotein that contains 12 hydrophobic membrane-spanning domains. To date, at least two other GABA transporter cDNAs have been cloned 195 , but the physiological and pharmacological significance of this heterogeneity is unknown. Nonetheless, specific inhibitors of GABA uptake that directly bind to the transporter itself have been synthesized, and several have been shown to have anticonvulsant and antinociceptive properties in laboratory animals 196, 197 . b) GABA receptors GABA is a highly flexible molecule and, thus, can exist in many low-energy conformations. Conformationally restricted analogues of GABA have been used to help identify three major GABA receptors, termed GABA A , GABA B and GABA C receptors [198] [199] [200] . GABA A and GABA C receptors are members of a superfamily of transmitter-gated ion channels that include nicotinic acetylcholine, strychninesensitive glycine and 5HT 3 receptors 201, 203 . On the other hand, GABAB receptors are seven transmembrane receptors that are coupled to G-proteins and activate second messenger systems and Ca ++ and K + ion channels. These receptors resemble mGluRs and develop before GluR 203 . c) GABA A receptors: physiology to pharmacology GABA A receptors are hetero-oligomeric chloride channels that are selectively blocked by the alkaloid bicuculline and modulated by steroids, barbiturates and benzodiazepines 204, 205 . To date, 16 human GABA A receptor cDNA have been cloned. They are ionotropic receptors leading to increased Cl -ion conductance 206 . Activation of the GABA A receptor by an agonist results in an increase in Cl -ion conductance via the receptor-gated ion channel or pore. This increase in Cl -ion conductance, which requires the binding and cooperative interaction of two molecules of GABA, is actually due to an increase in the mean open time of the Cl -ion channel itself 206 . The increase in Cl -ion conductance observed following activation of GABA A receptors results in a localized hyperpolarization of the neuronal membrane and therefore leads to an increase in the threshold required for excitatory neurotransmitters to depolarize the membrane in order to generate an action potential. This decrease in neuronal membrane excitability results in the inhibitory actions of GABA 198 . A variety of GABA receptor agonists have been discovered and have been shown to selectively activate GABA A receptors. Muscimol, a rigid GABA analogue isolated from the hallucinogenic mushroom Amanita muscaria, is one of the most selective and potent GABA agonists known. Muscimol is also not a substrate for the G A B A t r a n s p o r t e r , w h i c h m a k e s i t u s e f u l f o r electrophysiological and biochemical studies. Both competitive and noncompetitive GABA A receptor antagonists also have been described 207 . Heteropentamers of α1-6, β 1 -4 , γ 1 -4 , δ , a n d ρ p r i m a r i l y i n t h e r e t i n a . Many receptor subtypes contain α , β, and γ in a pentameric arrangement.
In recombinant systems, both the α and β subunits are required for the benzodiazepine (valium and librium) site. Barbiturates (Phenobarbital, pentobarbital) bind to α and β subunits.
Both of these drugs enhance channel opening and the effect of the drugs at any given synapse depends on the subunit composition of the GABA receptors there.
GABA B These receptors are largely inhibitory by opening K + channels or closing Ca ++ channels. Many compounds have been shown to augment GABAm e d i a t e d C l -i o n c o n d u c t a n c e s e l e c t i v e l y a t pharmacologically relevant concentrations. There is now considerable evidence that a number of other sedativehypnotic-anesthetic drugs also interact with GABA A receptors e.g., benzodiazepines, and several other compounds such as barbiturates, alcohols and anesthetics, have been shown to bind to, and affect, other receptors and channels as well. Therefore, the GABA A receptor can be positively or negatively modulated by compounds, which range in activity from full agonists to full inverse agonists 208, 209 . Full agonists have sedative-anesthetic properties, whereas full inverse agonists are convulsants 210 .
It is now thought that GABA A receptors are involved in at least some forms of human anxiety.
The large numbers of drug recognition sites associated with GABA A receptors, which are clearly distinct from those that recognize GABA itself, have led several investigators to propose the existence of endogenous receptor ligands. Several have been identified; however, with the possible exception of two, there is little compelling evidence at present that any interact with GABA A receptors in vivo. One of these ligands is an endogenous peptide diazepam-binding inhibitor (DBI), which was shown to interact with GABA A receptors and to have anxiogenic properties similar to inverse agonists 211 . The other postulated endogenous ligands include two natural reduced steroid metabolites of progesterone and deoxycorticosterone: allopregnanalone and allotetrahydrodeoxycorticosterone 212 . These neuroactive steroids bind with high affinity to GABA A receptors and have barbiturate-like actions in augmenting GABA-mediated responses 213 . The plasma and brain levels of these neuroactive steroids increase dramatically following exposure of rats to various stressors. Plasma allopregnanolone levels are also quite high during the third trimester of pregnancy, and they decrease dramatically following parturition 213 . However, none of these putative natural ligands have yet been unequivocally demonstrated to sub serve any physiological function.
Bicuculline is the prototypical competitive antagonist and directly competes with GABA for binding to the receptor complex. Bicuculline reduces both the frequency and mean open time of the GABA-gated Cl -ion channel. Picrotoxin and other extremely potent cage convulsants such a s t -b u t y l b i c y c l o p h o s p h o r o t h i o n a t e ( T B P S ) a r e noncompetitive GABA receptor antagonists that do not compete directly with GABA for its recognition sites but, instead, bind to separate and distinct recognition sites associated with the receptor complex 214 . O t h e r s e l e c t i v e a n t a g o n i s t s , s u c h a s t h e imidazobenzodiazepine Ro15-1788 (flumazenil), bind with high affinity to GABA A receptors but are devoid of intrinsic activity of their own 209 . However, these antagonists completely block the actions of benzodiazepine receptor agonists in augmenting GABA-mediated responses. Selective antagonists such as flumazenil also reverse the actions of inverse agonists. Not surprisingly, both classes of GABA A receptor antagonists produce seizures when administered to laboratory animals. The affinity of convulsants for GABA A receptors is so high that they have proven to be useful radioligands for measuring GABA A receptors in vitro and for their subsequent biochemical and pharmacological characterization 214 . Ethanol has been shown by several investigators to augment GABA-activated Cl -ion conductance in a variety of intact and isolated neuronal membrane preparations 215 . Concentrations of ethanol (10-100 mM) weakly augment GABA-activated Cl -ion conductance, as do longer chainlength alcohols and general anesthetics 216, 217 . Moreover, several imidazobenzodiazepine inverse agonists of the benzodiazepine receptor have been reported to antagonize the sedative effects of ethanol 215 . This finding is further evidence implicating the GABA A receptor as one of the key central sites mediating at least some of ethanol's neuropharmacological effects. The effects of ethanol on GABA A receptors, coupled with its more recently described actions in inhibiting Glu (NMDA) receptor-mediated depolarizing events 217 , likely contribute to the anxiolytic and sedative effects of alcohols.
To date, five distinct classes of polypeptide subunits (α, β, γ, δ, and ρ) have been cloned and multiple isoforms of each have been shown to exist 218 . There is approximately 70% sequence identity between the polypeptide subunits within a given class, but only approximately 30% between classes [219] [220] [221] . Subunit heterogeneity seems also to be relevant to the pharmacological differences observed between drugs that interact with GABA A receptors such as the benzodiazepines 222, 223 . Several of the subunits of the GABA A receptor have been cloned 201, 205 . The deduced AA sequences of the α-and β-subunit cDNAs isolated indicated that each subunit was approximately 50-60 kDa in size and had four α-helical h y d r o p h o b i c m e m b r a n e -s p a n n i n g s e q u e n c e s o f approximately 20-30 AAs. The predicted structure of the receptor was based on strong evidence that the GABA A receptor is a member of a large superfamily of ligand-gated ion channels, which includes the nicotinic-cholinergic, ionotropic Glu, and glycine receptors 201, 202 . In contrast, GABA C receptors represent a relatively simple form of transmitter-gated Cl -ion channel made up of a single type of protein subunit. Two human GABA C receptor cDNA have been cloned 200 . These receptors are not blocked by bicuculline nor do steroids, barbiturates or benzodiazepines modulate them. Instead, GABA C receptors are selectively activated by the conformationally restricted analogues of GABA in the folded conformation cis-4-aminocrotonic acid and (1 S, 2 R)-2-(aminomethyl)-1-carboxycyclopropane. (1,2,5,6-Tetrahydropyridine-4-yl) methylphosphinic acid, a methylphosphinic acid analogue of GABA in a partially folded conformation, is a selective antagonist at GABAC receptors 198, 224 . e) GABA B receptors GABA B receptors are seven transmembrane receptors that are coupled to G-proteins and activate second messenger systems and Ca ++ and K + ion channels 225 . Three GABA B receptor proteins have been cloned and these resemble metabotropic GluRs 199, 226 . GABA B receptors are heterooligomeric receptors made up of a mixture of a combination of the subunits, which are selectively activated by baclofen and CCGP27492 and are blocked by phaclofen, the phosphonic acid analogue of baclofen; hence, GABA B is found in central and peripheral nervous tissue 226 .
3) Glycine
Glycine (Gly), also known as aminoethanoic acid, is a non-polar, sweet tasting, AA derived from the alkaline hydrolysis of gelatin. It is the simplest of the AAs as its side chain is only a hydrogen atom. More complex AAs are constructed on the basic glycine structure. Since Gly has no side chain, it can enter spaces where no other AA can, e.g., only glycine can be the internal AA of the collagen helix accounting for about one third of the mass of collagen. Gly is conserved among species at certain positions in some proteins, e.g., cytochrome c, myoglobin, and hemoglobin 227 . a) Glycine: synthesis and uptake Gly is the major inhibitory neurotransmitter in the brainstem and spinal cord, where it participates in a variety of motor and sensory functions. It also functions as a co agonist at the NMDA subtype of GluR in the forebrain, where it promotes the actions of Glu, the major excitatory neurotransmitter. Thus, Gly subserves both inhibitory and excitatory functions within the CNS.
Gly is formed from serine by the enzyme serine hydroxymethyltransferase (SHMT) and like GABA, is released from nerve endings in a Ca ++ -dependent fashion. Its uptake has been demonstrated in the brainstem and spinal cord in regions where there are also high densities of inhibitory glycine receptors. The actions of Gly are terminated primarily by reuptake via Na + /Cl --dependent, high-affinity glycine transporters.
Glycine transporters have been cloned and expression shown in the CNS and in peripheral tissues 228, 229 . These glycine transporters are members of the large family of Na + / Cl --dependent neurotransmitter transporters, and both share approximately 50% sequence identity with the GABA transporters discussed above. Two glycine-cloned transporters have been named GLYT-1 and GLYT-2 both of which have similar kinetic and pharmacological properties 228 . Studies have inferred that GLYT-1 is primarily a glial glycine transporter whereas GLYT-2 is primarily a neuronal transporter. The mapping of both glycine transporter mRNAs, as well as the glycine receptor subunit mRNAs, confirm the importance of this neurotransmitter in the brainstem and spinal cord, but support a more widespread distribution in supraspinal brain regions than was previously suspected 230 . b) Glycine receptors
The glycine receptor was first successfully dissolved and purified using affinity purification over an affinity matrix derivatized with aminostrychnine 231 . This affinitypurified glycine receptor was shown to consist of two polypeptide subunits of approximately 48 kDa (α) and 58 kDa (β), respectively.
Reconstitution of these polypeptide subunits into lipid vesicles resulted in functional receptors, and intramolecular cross-linking experiments suggested that the native glycine receptor is a pentameric structure. Photo affinity labeling of the glycine receptor with [ 3 H]strychnine revealed that both the strychnine and Gly binding sites are located on the 48-kD a subunit. As would be expected, purification of the α-and β-receptor subunits was followed closely by their molecular cloning 231 .
The deduced AA sequences of the α-and β-glycinereceptor subunits predict structures quite homologous to the subunits of other ligand-gated ion channels, including the GABA A receptor 232 . Each subunit has four hydrophobic membrane-spanning sequences, and each shares considerable sequence identity with the other. Several glycine-receptor α-subunit variants have been identified (α1-4), and, not surprisingly, they differ in their pharmacological properties and level of expression. As mentioned, both the agonist and antagonist binding sites are located on the α-subunit, but at different AAs 233 . Interestingly, glycine receptors comprised of α1 subunits are efficiently gated by taurine and β-alanine, whereas α2-containing receptors are not 231 . The α1 and α2
genes are expressed in the adult and neonatal brain, respectively. Here the β-subunit transcript is expressed at relatively high levels in the cerebral cortex and cerebellum, where no a transcripts or specific [ 3 H]strychnine binding sites have been observed. Co expression of β subunits with α-subunits, as opposed to homo-oligomeric α-subunit glycine receptors, results in glycine receptors with pharmacological properties quite similar to native glycine receptors. Nonetheless, the widespread distribution of β-subunit mRNA in the brain suggests that other, perhaps strychnine-insensitive glycine receptor isoforms will be found.
The expression of α1 and α2 subunits is regulated developmentally with a switch from the neonatal α2 subunit [strychnine-insensitive] to the adult α1 form [strychninesensitive] at about 2 weeks postnatally in the mouse 231 . The timing of this switch over corresponds with the development of spasticity in the mutant spastic mouse 234 , prompting speculation that insufficient expression of the adult isoform may underlie some forms of spasticity 230 . Electrophysiological studies in rodent spinal cord neurons have demonstrated that Gly activates the Cl -ion conductance 231 . Like GABA, this increase in Cl -ion conductance results in a hyperpolarization of the neuronal membrane and an antagonism of other depolarizing stimuli.
As indicated above, other α-and β-AAs, including β-alanine and taurine, also activate glycine receptors, but with lower potency 231, 235 . Inhibitory glycine receptors are blocked by the plant alkaloid strychnine, which was also first used to label glycine receptors in spinal cord membranes 217, 236 . Strychnine poisoning results in muscular contractions and tetany as a result of glycinergic disinhibition and over excitation. c) Glycine as a co-agonist
Gly is a co-agonist at NMDA receptors at a strychnineinsensitive recognition site (glycine B) and its presence at moderate nM concentrations is a prerequisite for channel a c t i v a t i o n b y G l u o r N M D A 2 3 7 . P h y s i o l o g i c a l concentrations reduce one form of relatively rapid NMDA receptor desensitization.
Recently it has been suggested that D-serine may be more important than Gly as an endogenous co-agonist at NMDA receptors in the telencephalon and developing cerebellum. There is still some debate as to whether the glycine B site is saturated in vivo 237 but it seems likely that the degree of NMDA receptor activation varies depending on regional differences in receptor subtype expression and local Gly or D-serine concentrations. Moreover, Gly concentrations at synaptic NMDA receptors could be finely modulated by local expression of specific glycine transporters such as GLYT1 238 .
Glutamate Receptors
Glutamate receptors (GluRs), which are important in n e u r a l p l a s t i c i t y , n e u r a l d e v e l o p m e n t , a n d neurodegeneration 2 3 9 -2 4 1 , have been individually characterized by their sensitivity to specific Glu analogues and by the features of the Glu-elicited current. GluR agonists and antagonists are structurally similar to Glu, which allows them to bind onto the same receptors [242] [243] [244] . Activation of GluRs has been shown to mediate a large number of neuronal processes such as long-term potentiation and ischemic damage 245 . Two classes of GluRs have been characterized based on studies in the CNS: ionotropic (iGluRs) and metabotropic (mGluRs). These receptor types are similar in that they both bind Glu, and Glu binding can influence the permeability of ion channels. However, there are several differences between the two classes 246 . Their cloning has revealed the molecular diversity of the gene families encoding various receptor types that are responsible for the pharmacological and functional heterogeneity in the brain and other tissues 21, [24] [25] [26] 31, 33, 55, 56, 156 .
Ionotropic glutamate receptors (iGluRs)
The iGluRs are ligand-gated ion channels that mediate the vast majority of excitatory neurotransmission in the brain. The iGluRs contain integral cationic channels associated with ligand binding sites that mediate rapid synaptic transmission. The structure and how it relates to the function of these receptors has received recent attention and the reader is directed to these publications for further details [247] [248] [249] .
The iGluR family is classified into three major subtypes a c c o r d i n g t o t h e i r s e q u e n c e s i m i l a r i t i e s , t h e i r electrophysiological properties, and their affinity to selective agonists: N-methyl-D-aspartate (NMDA), α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and kainate (Ka) receptors 21, 22, 25, 26 . All iGluRs can form heteromeric subunit assemblies, composed of different subunits, which have different physiological and pharmacological properties and are differentially distributed throughout the CNS 25, 50, 237, [250] [251] [252] [253] . Both AMPA 254 and NMDA receptors 255 are probably largely formed from tetrameric, heteromeric assemblies of different subunits 256 . Changes in these receptors are probably mediated through nuclear transcription factors 257 . The membrane channels associated with these receptors exhibit varied pharmacological and electrophysiological properties, including ionic channel selectivity to sodium (Na + ), potassium (K + ) and Ca ++21,22,25,26,33 . The non-NMDA receptors control a nonselective cationic channel permeable to Na + and K + , whereas NMDA is more permeable to Ca ++ ions than either AMPA or Ka 21, 22, 25, 26 . Recombinant technology has identified several gene families encoding iGluRs: AMPA family is composed of GluR 1-4 (GluRA-D); Ka family includes GluR 5-7 and Ka 1-2; NMDA includes NMDAR 1 and NMDAR 2A-D.
NMDAR 1, the most tightly regulated neurotransmitter receptor, forms the channel where other subunits (NMDA 2A-D) are involved in the receptor modulation. It is the most intensively studied and complex receptor and is linked to the Na+ and Ca ++ ion channel that has 5 distinct binding sites for endogenous ligands that influence the opening of these channel 21, 22, 25, 33 . These binding sites include 2 different agonist recognition sites, one for Glu and one for Gly, a polyamine regulatory site that promotes receptor activation. The remaining sites are separate recognition sites for Mg ++ , Zn ++ , and phencyclidine (PCP), which inhibits ion flux through agonist bound receptors 21, 22, 25, 26, 33, 250 . The complexity of these iGluR families is further increased by alternate splicing, RNA editing and posttranslational modifications such as phosphorylation, glycosylation and palmitoylation. Each of these modifications is important in the regulation of channel functions 247, 248 . Within each family, GluRs subunits can also form homo-oligomeric or heteroligomeric channels that exhibit different functional properties depending on the subunit composition. For example, the presence of the GluR 2 s u b u n i t d e c r e a s e s C a + + p e r m e a b i l i t y o f A M P A channels 21, 22, 25, 33 . Table 4 lists the iGluRs. Learning and memory depend on persistent changes in synaptic strength that require neuronal gene expression. AMPA-and NMDA-type GluRs have distinct roles in controlling synaptic strength: AMPA receptors effect shortterm changes in synaptic strength, whereas NMDA receptors regulate genes that are required for the long-term maintenance of these changes 259 .
1) Diversity of the ionotropic glutamate receptors
The iGluRs are an extremely diverse group of receptors, a diversity that is generated both before and after gene transcription. Glu binding onto an iGluR directly influences ion channel activity because the receptor and the ion channel form one complex. These receptors mediate fast synaptic transmission between neurons. Each iGluR is formed from the co-assembly of multimeric individual subunits, the structures of which affect the receptor function 249 .
T h e a s s e m b l e d s u b u n i t s m a y o r m a y n o t b e homologous, with the different combinations of subunits, e.g., NR2A-D is produced from four genes, resulting in channels with different characteristics 57, 240, [260] [261] [262] [263] . However, following gene transcription, the resultant pre-mRNA may be modified. For example, different regions of this mRNA molecule can be spliced together, giving rise to multiple mRNAs that are translated into different proteins.
This phenomenon is known as "splice variation" and is a very common finding among neuroreceptors. The Cterminus of the iGluRs is the site of extensive splice variation, which could have important functional consequences, as the C-terminus is also the site for multiple protein-protein interactions, e.g., GluR2. Thus, different splice variants may interact differently with the same set of proteins leading to, for instance, differential subunit localization 246 . A further modification leading to diversification is RNA editing, in which selected nucleotides in the mRNA sequence transcribed from the gene sequence are enzymatically modified, changing the AA for which it was coded. Such an event has fundamental consequences for the Ca ++ permeability of subunits such as the AMPA type subunit GluR2 and the Ka receptor subunit GluR5 264 .
2) Synaptic plasticity In many regions of the CNS, limited Ca ++ influx through NMDA receptors can trigger two forms of synaptic plasticity: LTP and LTD. LTP and LTD are believed to resemble some elementary features of memory formation at the neuronal leve l91, [265] [266] [267] [268] [269] . Voltage-dependent blockade of NMDA receptors by Mg ++ and their high Ca ++ permeability renders them inherently suited for their role in mediating synaptic plasticity 271 . NMDA receptor channels are only activated in the presence of a local strong depolarization induced by strong AMPA receptors activation and concurrent GABAergic disinhibition via feedback effects of GABA on GABA B autoreceptors.
As a result, the Mg ++ blockade of NMDA receptors is transiently fully relieved allowing Ca ++ to flow into the postsynaptic neuron. This Ca ++ influx triggers a cascade of secondary messengers which ultimately activate a number of enzymes such as protein kinase C (PKC), phospholipase A2 (PLA2), phospholipase C (PLC), Ca ++ -calmodulindependent protein kinase II (CaM kinase II), and others [272] [273] [274] [275] [276] [277] [278] . Consequently, these processes lead to fixation of changes in postsynaptic AMPA receptors such as an increase in their affinity and number [279] [280] [281] [282] [283] , and possibly through retrograde signals from arachidonic acid and nitric oxide 284 , modulate presynaptic glutamatergic terminals influencing [285] [286] [287] [288] [289] [290] . There is accumulating evidence that LTP and LTD share some common mechanisms, although LTD occurs with increases in postsynaptic Ca ++ , which are insufficient to induce LTP [291] [292] [293] [294] [295] [296] [297] [298] [299] [300] . LTP and LTD have been extensively studied as cellular models of learning and memory.
Although hippocampal LTP and spatial learning are impaired by NMDA receptor blockade 270 , learning deficits can be almost completely prevented if rats are previously trained in a different water maze 301, 302 . Therefore, NMDA receptors may not be required for encoding the spatial representation of a specific environment but rather in other forms of memory important for learning this task 303 . Further evidence indicates that LTP is not only important for synaptic plasticity in the mature CNS but also in the formation of conducting glutamatergic synapses in the developing mammalian brain 397 . One form of hippocampal LTP involves the activation of the NMDA receptors and a rise in postsynaptic Ca ++ in the CA1 region but there is still considerable debate as to the site at which the increase in synaptic strength is expressed [304] [305] [306] [307] . Presynaptic mechanisms, which can be measured at excitatory synapses on cultured hippocampal neurons by analysis of the progressive block of NMDA receptormediated synaptic currents by the irreversible open channel blocker, dizocilpine ((+) MK-801), should be reflected in a change in release probability 398 . This technique was used to demonstrate that release probability was not affected after the induction of LTP, making a presynaptic mechanism unlikely 308 . In fact, other authors indicate that a high proportion of synapses in hippocampal area CA1 transmit through NMDA receptors but not AMPA receptors, making these synapses effectively non-functional at normal resting potentials due to Mg ++ blockade [309] [310] [311] [312] . These silent synapses acquire AMPA-type responses following LTP induction.
This form of LTP is accompanied by an increase in the conductance of postsynaptic AMPA receptors 313 . When NR1, NR2A, NR2B, NR2C, NR2D  GLUR1, GLUR2, GLUR3, GLUR4  GLUR5, GLUR6, GLUR7, ++ , which can act as a second messenger. The kinetics of gating is relatively slow compare to those of the AMPA/ kainite receptors. The entry of Ca ++ (and Na + ) through the channels is subject to a voltage dependent block by Mg ++ such that there is significant Ca ++ entry only if the neuron is depolarized. The depolarization can be achieved by the action of the AMPA receptor channels and, to a lesser extent, by the NMDA receptor channels. The channels also require the presence of glycine as a coagonist.
Heterotetramers or heteropentamers of R1, R2A, R2B, R2C, and R2D. Alternatively known as NR1, NR2A-NR2D and MDAR1, NMDAR2A-NMDAR2D. Numerous splice variants can be mixed and matched.
A M P A / Kainate (Ka) (non-NMDA) AMPA and kainite are a family of ligand-gated that are activated physiologically by Glu. They are identified pharmacologically by agonist actions of AMPA and kainate and their insensitivity to NMDA. Agonist binding opens cation channels that pass Na + , K + , and sometimes Ca ++ . The kinetics of the response is fast (quick on and quick off) compared to those of NMDA receptors. Thus, they are very effective at depolarizing neurons and mediate fast EPSCs. Previously, what is now called AMPA/kainate receptors formed two classes based on pharmacology: kainate receptors and AMPA/kainate/ quisqualate receptors. More recently, molecular classification has grouped these into a single group.
Multi subunit tetramers or pentamers of GluR1 -GluR7, KA1, KA2. There is a variety of molecular mechanisms result in numerous splice variants of these proteins. In addition, the GluR and Ka proteins can combine in numerous ways. The presence of a Ka subunit is sufficient but not necessary to make a channel with high sensitivity to kainate.
Kainate is a potent c o n v u l s a n t a n d neurotoxin. AMPA antagonists are neuroprotective in animal models of cerebral ischemia.
viewed together, these findings challenge the dogma that LTP in CA1 involves a presynaptic modification, and suggest instead a simple postsynaptic mechanism for both induction and expression of LTP.
3) NMDA receptors
The NMDA receptor is perhaps the best characterized of the iGluR 251, 314 , in part due to the existence of selective agonists and antagonists. NMDA receptors are ubiquitous 315 and are found with relative ease in the cerebral cortex within the Schaffer collaterals of the CA3 -CA1 projection within the hippocampus. These receptors play a role in LTP; a phenomenon associated with learning and memory function and increased neuronal activity such as in "kindling."
NMDA receptors are quite diverse 316 and are composed of assemblies of NR1 subunits and NR2 subunits, which can be one of four separate gene products (NR2A-D). Expression of both subunits is required to form functional channels. The Glu-binding domain of the receptor is formed at the junction of NR1 and NR2 subunits; hence, the need for expression of both subunits. In addition to Glu, the NMDA receptor requires a co-agonist, Gly, to bind to allow the receptor to function. The Gly-binding site is found on the NR1 subunit. The NR2B subunit also possesses a binding site for polyamines, regulatory molecules that modulate the functioning of the NMDA receptor 317 . NMDA receptors are inactive at resting membrane potentials due to a voltage-dependent block of ion flow through the channel pore by Mg ++ ions. Sustained activation of AMPA receptors by a train of impulses arriving at a presynaptic terminal depolarizes the post-synaptic cell, releasing the channel inhibition and thus allowing NMDA receptor activation. Unlike GluR2-containing AMPA receptors, NMDA receptors are permeable to Ca ++ and other ions. Therefore NMDA receptor activation leads to a Ca ++ influx into the post-synaptic cells.
Glu binding onto an NMDA receptor also opens nonselective cation channels, resulting in a conductance increase. However, the high conductance channel associated with these receptors is more permeable to Ca ++ than Na + ions 318 and NMDA-gated currents typically have slower kinetics than kainate-and AMPA-gated channels. As the name suggests, NMDA is the selective agonist at these receptors. The compounds MK-801, AP-5 (2-amino-5-phosphonopentanoic acid), and AP-7 (2-amino-7-phosphoheptanoic acid) are NMDA receptor antagonists.
NMDA receptors are structurally complex, with separate binding sites for Glu, Gly, Mg ++ , Zn ++ , and a polyamine recognition site. There is also an antagonistbinding site for PCP and MK-801 319 . The Glu, Gly, and Mg ++ binding sites are important for receptor activation and gating of the ion channel. In contrast, the Zn ++ and polyamine sites are not needed for receptor activation, but affect the efficacy of the channel.
Zn ++ blocks the channel in a voltage-independent manner 3 2 0 , whereas the polyamine site 3 2 1 , 3 2 2 binds compounds such as spermine or spermidine, either potentiating 321, 322 or inhibiting 322 the activity of the receptor. Potentiation or inhibition depends on the combination of subunits forming each NMDA receptor 322 . The Glu, Gly, and Mg ++ binding sites confer both ligand-gated and voltage-gated properties onto NMDA receptors. NMDA receptors are ligand-gated because the binding of GluR (ligand) is required to activate the channel with the presence of micromolar concentrations of Gly, which must also be present 323, 324 . The requirement for both Glu and Gly makes them co-agonists 324 at NMDA receptors. Mg ++ ions provide a voltage-dependent block of NMDAgated channels 325 . NMDA receptors are highly permanent for Ca ++ ions. They show slower gating kinetics with the channel blocked in a voltage and use-dependent manner by physiological concentrations of Mg ++ ions 325 . These properties make them ideally suited for their role as a coincidence detector underlying synaptic plasticity in learning, chronic pain, drug tolerance and dependence 83, 84, 90, 91, 252, 266 . NDMA receptors were originally thought to belong exclusively in neurons. However, recent studies have found functional NMDA receptors in brain microglia, astrocytes, and oligodendrocytes, but glial and neuronal NMDA receptors are functionally and structurally different. Glial receptors are weakly sensitive to the extracellular Mg ++ block in comparison to neurons, indicating a predominant expression of the NR3 receptor subunit.
In the cortex, astroglial NMDA receptors are activated u p o n p h y s i o l o g i c a l s y na p t i c t r a n s m i s s i on . T h e physiological relevance of NMDA receptors in the white matter remains unknown; their activation upon ischemia triggers Ca ++ -dependent damage of oligodendrocytes and myelin 326 . a) NDMA subunits Two major subunit families of NMDA designated NR1, NR2, as well as a modulatory subunit designated NR3, have been cloned. Most NMDA functional receptors are formed by combination of NR1 and NR2 subunits, which express the Gly and Glu recognition sites respectively 327, 328 . NR1 is more concentrated in rostral structures such as cortex, caudate, and hippocampus, while the latter are principally found in more caudal regions such as thalamus 329 , colliculi, locus coeruleus and cerebellum 330 . The NR2 subfamily consists of four individual subunits: NR2A to NR2D 263 . Various heteromeric NMDA receptor channels formed by combinations of NR1 and NR2 subunits are known to differ in gating properties, Mg ++ sensitivity, and pharmacological profile 331 . Of the NR2 group, NR2A is distributed ubiquitously, as is NR1, with greatest densities occurring in hippocampal regions. NR2B is expressed predominantly in forebrain but not in cerebellum where NR2C predominates. The spinal cord expresses high levels of NR2C and NR2D 332 and these subunits may form heteroligomeric receptors with NR1 plus NR2A, which would provide a basis for the development of drugs selectively aimed at spinal cord di sorders 3 3 3 . N R3 (NRL or Ch i-1 ) is expressed predominantly in the developing CNS. NR3 does not seem to form functional homomeric Glu-activated channels, but the co-expression of NR3 with NR1 plus NR2 subunits decreases any response magnitude [334] [335] [336] [337] .
4) AMPA receptors
AMPA receptors are involved in mediating most forms of fast glutamatergic neurotransmission, which corresponds to a Ca ++ influx 338 , and the inward rectification of both AMPA and kainate subtype GluRs are generated by polyamine-mediated ion channel block 339 . In fact, AMPA receptor activates a G-protein that suppresses a cGMP-gated current 340 . Four known subunits GluR1 to GluR4, sometimes referred to as GluRA to GluRD, are widely, but differentially, distributed throughout the CNS 25 . The types of subunits forming these receptors determine their biophysical properties and pharmacological sensitivity.
Two alternative splice variants of GluR1 to GluR4 subunits designated as 'flip' and 'flop' have been shown to differ in their expression throughout the brain and during development and to impart different pharmacological properties AMPA receptors also play an important role in memory function 3 4 1 , 3 4 2 . They are localized in the hippocampus and striatum and also may play a role in the generation of seizures 263, 338, 343 . Like all iGluR subunits, but in contrast to other ligand gated ion channel subunits such as those forming the GABA A receptor, iGluR subunits have an extracellular Nterminus and an intracellular C-terminus. The ligandbinding domain is made up from N-terminal regions S1 and S2, although it is possible that the binding site is spread across more than one subunit like the NMDA receptor. All AMPA receptor subunits exist as two splice variants, flip and flop. The alternative splice cassette is found at the Cterminal end of the loop between TMIII and TMIV. Although only a few AAs are changed in the receptor subunits, the effect can be quite dramatic resulting in altered desensitization kinetics.
Native AMPA receptor channels are impermeable to Ca ++ , a function controlled by the GluR2 subunit. The Ca ++ permeability of the GluR2 subunit is determined by posttranscriptional editing of the GluR2 mRNA, which changes a single AA in the TMII region from glutamine (Q) to arginine (R). This event is the so-called Q/R editing siteGluR2(Q) is Ca ++ permeable whilst GluR2(R) is not. Almost all the GluR2 protein expressed in the CNS is in the GluR2(R) form, giving rise to Ca ++ impermeable AMPA receptors. This observation, along with the interactions with other intracellular proteins, makes GluR2 perhaps the most important AMPA receptor subunit.
5) Kainate receptors
Kainate (Ka) receptors constitute a separate group from the NMDA and AMPA receptors, although they share many of the same structural characteristics 344 . Ka and AMPA receptors are localized in the hippocampus and striatum and also may play a role in the generation of seizures 345 . Ka is used as a neurotoxin in basic research due to its ability to destroy cells at the site of injection while leaving axons of passage intact. Ka receptors are built from multimeric assemblies of GluR5-7 and KA-1/2 subunits. Like the other iGluRs, they possess an extracellular N-terminus. This terminus forms the ligand binding domain and a re-entrant loop (TMII), together with a loop between TMIII and TMIV, which forms the lining of the pore region in the ion channel. Ka also undergoes both splice variation and RNA editing, giving rise to a large number of possible receptors with differing pharmacological and functional properties 346 . Ka receptors were previously believed to be largely presynaptic. Activation of these Ka receptors facilitated transmitter release at such sites as the dorsal root ganglia 347 . Short-term synaptic facilitation is reduced in knockout mice lacking the GluR6, but not the GluR5, Ka receptor subunit suggesting that Ka receptors act as presynaptic autoreceptors o n m o s s y f i b e r t e r m i n a l s t o f a c i l i t a t e s y n a p t i c transmission 348 , but inhibition of GABA release 349 . Also they are involved post synaptically in neurotransmission in some pathways 345, [350] [351] [352] .
Metabotropic glutamate receptors (mGluRs)
The mGluRs were discovered and established as a new type of excitatory AA receptor by their unique coupling mechanism and pharmacological characteristics. mGluRs are a family of eight single polypeptide chain receptors that function via coupling to G-proteins 353 . Members of this family have unique pharmacological properties and function to modulate the presynaptic release of Glu and the postsynaptic sensitivity of the cell to Glu excitation 22, 25, 33, 34, 354, 356 . They exert their effects either on the second messengers or ion channels via the activation of the GTP-binding proteins and regulate the synthesis of different intracellular second messengers such as IP3, cAMP or cGMP 22, 25, 33, 34, 56 . Single mGluR proteins can cross talk with multiple second messengers in the same cell.
The mGluRs are densely expressed in medium spiny projection neurons of striatum. They have both chemical and electrical signaling properties 355 . Glu binding onto an mGluR opens non-selective cation channels more permeable to Na + and K + ions than Ca ++318 . mGluR binding elicits a rapidly activating inward and outward current and Ka, quisqualate, and AMPA are the specific agonists at these receptors; CNQX (6-cyano-7-nitroquinoxaline-2, 3-dione), N B Q X ( 1 , 2 , 3 , 4 -t e t r a h y d r o -6 -n i t r o -2 , 3 -d i o n ebenzo[f]quinoxaline-7-sulfonamide), and DNQX (6,7-dinitroquinoxaline-2,3-dione) are the antagonists 107, [356] [357] [358] [359] [360] [361] . In common with other G-protein coupled receptors (GPCRs), the mGluRs possess a 7 transmembrane domain motif (7-TMR) and an extracellular N-terminus and intracellular C-terminus. However, the mGluRs are much larger than GPCRs of the adrenergic type and the ligandbinding domain is located in the N-terminus, rather than in a pocket formed from the clustering of the 7-TMR region 362 . The eight functionally distinct mGluR subtypes are localized to specific neuron types at presynaptic and postsynaptic membranes, their physiological functions involving the generation of slow excitatory and inhibitory synaptic potentials, modulation of synaptic transmission, synaptic integration, and plasticity.
As with iGluRs, the mGluRs are classified into 4 groups (Group I -IV) based on AA sequence similarities, agonist pharmacology and the signal transduction pathways to which they are coupled 240 . Each receptor is formed from the co-assembly of several subunits 239, 240, 363 . To date, eight subunits (named mGluR1 through mGluR8) have been cloned 239, 260, [262] [263] [264] [265] [266] [267] . Briefly, Group I (mGluR 1, 5, and 6) stimulates inositol phosphate metabolism and mobilization of intracellular Ca ++ , Group II (mGluR 2 and 3) and Group III (mGluR 4, 6-8) are coupled to adenylcyclase 22, 25, 33, 56 , and Group IV is coupled to the activation of phospholipase D (PLD) 368 . The latter class is more efficiently activated by L-cysteinesulfonic acid (L-CSA) rather than Glu, which suggests that L-CSA may serve as an endogenous agonist of this receptor 55 . As with the iGluRs, the mGluRs also have a unique distribution in the CNS and retina, which reflects a diversity of function in normal and pathological processes. The mGluRs have certain features that distinguish them from the iGluRs. First, the mGluRs modulate the activity of neurons rather than mediate fast synaptic neurotransmission. Second, the distribution of the mGluRs is highly diverse and heterogeneous. Different subclasses are localized uniquely at both the anatomical and cellular levels. For example, mGluR 2 and 3 are found in high density in the cerebral cortex, whereas mGluR 4 is found in high density in the thalamus but not in the cortex and mGluR 6 is almost exclusively found in the retina.
Activation of mGluRs alters local transmitter release and behaviors of experimental animals. In particular, mGluRs regulate phosphorylation of several key signaling proteins, including protein kinases and transcription factors, resulting in significant changes in immediate early gene and neuropeptide gene expression in striatal neurons. The prominent involvement of mGluRs in genomic responses to synaptic stimulation is considered to play a pivotal role in the development of synaptic and neuronal plasticity underlying long-term adaptive changes in cellular physiology related to a variety of neurological disorders. mGluR also regulates dopamine transmission, an important factor in many neurological disorders 369 . Motor neuron activity changes significantly after administration of mGluR antagonists. Antagonists for Group II and for Group III mGluR enhance synaptic currents in rat spinal lumbar and cervical motor neurons [370] [371] [372] . This increased current is presumably caused by the blockade of presynaptic receptors, suggesting that endogenous activation of these receptors attenuates synaptic transmission. In phrenic motor neurons, the Group I mGluR antagonist (R,S)-1-aminoindan-1,5,dicarboxylic acid (AIDCA) significantly reduces excitatory postsynaptic currents amplitude, suggesting that postsynaptic Group I mGluR, along with various ionotropic receptors 373, 374 , are activated by endogenously released Glu during inspiration. Three groups of mGluR are functionally expressed in motor neurons to mediate differential effects on intrinsic and synaptic properties via distinct mechanisms operating at pre-or postsynaptic sites. The diversity of actions mediated by various receptor subtypes provides a wide dynamic range for modulation of motor neuron excitability.
The glutamate system: agonists and antagonists

1) iGluRs and mGluRs
As Glu, GluR, and GluTP are ubiquitous and have a plethora of effects, antagonists to GluR are under evaluation for a number of diseases. So far most efforts have been directed toward antagonism to the iGluR, but some effects have also been made with respect to the mGluR. Glu, NMDA, AMPA and Ka are the most commonly used GluR agonists. The purpose of developing antagonists is two fold: to enable investigation into the mechanism of action of the GluR and to hopefully develop new drugs targeting diseases know to have basis in altered Glu activity 47 . A summary of a sample of the GluR agonists and antagonists available can be seen in Table 7 .
The side effects of agonist over stimulation have been previously discussed under the section on excitatory amino acids (EAAs). Antagonists, which completely block NMDA receptors, cause numerous side effects such as memory impairment, psychomimetic effects, ataxia and motor i n c o o r d i n a t i o n a s t h e y i m p a i r n o r m a l s y n a p t i c transmission 375 .
2) Glycine
Most full glycineB antagonists, without intrinsic partial agonist activity, show very poor penetration to the CNS, although some agents with improved, but by no means optimal pharmacokinetic properties, have now been developed. Glycine B antagonists have been reported to lack many of the side effects classically associated with NMDA receptor blockade such as no neurodegenerative changes in the cingulate and retrosplenial cortex even after high 376 and no psychomimetic-like or learning impairing effects at anticonvulsive doses 237, [377] [378] [379] [380] . The improved neuroprotective therapeutic profile of glycine B full antagonists could be due to their ability to reveal glycinesensitive desensitization 381 . Kynurenic acid is an endogenous glycine B antagonist but it seems unlikely that concentrations are sufficient to i n t e r a c t w i t h N M D A r e c e p t o r s u n d e r n o r m a l conditions 237, 382 . However, concentrations are raised under certain pathological conditions 237, 382 and interactions with other receptors such as α7 neuronal nicotinic have been reported at lower concentrations 237, 382, 383 . D-cycloserine and (+R)-HA-966 are partial agonists at the glycine B site with different levels of intrinsic activity of 57% and 14% respectively in cultured hippocampal neurons 384 . Although these systemically active partial agonists do not induce receptor desensitization [384] [385] [386] , they have favorable therapeutic profiles in some in vivo models 387, 388 . In part this positive effect may be due to their own intrinsic activity as agonists at the glycine B site, which would serve to preserve a certain level of NMDA receptor function even at very high concentrations [389] [390] [391] . Although ACPC has been reported to be a partial agonist with very high intrinsic activity, it is probably really a full agonist at the glycine B site and actually behaves as an a n t a g o n i s t i n s o m e i n v i v o m o d e l s , r e s u lt i n g i n neuroprotection and anticonvulsive effects, which are likely to be mediated via competitive antagonistic properties at higher concentrations 392 . The consistent observation that chronic treatment with ACPC is neuroprotective could be because it desensitizes or uncouples NMDA receptors 393, 394 or may be related to an increase in the relative levels of NR2C expression 390 .
Dose-response
D-cycloserine shows agonist like features at low doses, while with increasing dosing antagonistic effects predominate 387 . Such findings are often falsely interpreted to be "typical" for partial agonists: agonism at low and antagonism at high doses. However, partial agonism actually means that an agent reaches a ceiling, non-maximal effect at higher doses. That is its intrinsic activity is limited compared with a full agonist, so that it will antagonize receptor activation at high concentrations but facilitate at low concentrations 384, 385 . The consistent biphasic effects of D-cycloserine seen in vivo may be related to different affinities and intrinsic activities at NMDA receptor subtypes. D-cycloserine is a partial agonist for the murine equivalents of NR1/2A and NR1/2B heteromers [38% and 56% intrinsic activity compared to Gly 10 µM] but is more effective than Gly at NR1/2C (130%) 395 . This effect is accompanied by higher affinity at NR1/2C receptors -NR1/2C > NR1/2D >> NR1/ 2B > NR1/2A 395 . In contrast, similar data showed that the intrinsic activity at NR1/2C was even higher (192%) 396 . Therefore, it is likely that the biphasic effects seen in vivo are due to agonistic actions at NR1/2C receptors at lower doses and inhibition of NR1/2A and NR1/2B containing receptors at higher doses.
In conclusion, the glutamate system is central to many neurotransmission processes, and this review has attempted to summarize some aspects of the complex glutamate system. As we learn more regarding this system, it is probable that current and future development of agonists and antagonists for treatment of a number of diseases will occur. T he s e c o nd p a r t of t hi s r e v ie w w il l a d dr e s s t h e pathophysiology and pathology of the GluRs.
